Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity.
about
Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbationAntibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbationToward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: a computational approach and GFP-reporter cell-based assayAmgRS-mediated envelope stress-inducible expression of the mexXY multidrug efflux operon of Pseudomonas aeruginosa.Risk factors for chronic kidney disease in adults with cystic fibrosis.d-Methionine reduces tobramycin-induced ototoxicity without antimicrobial interference in animal models.Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis.Prospects for circumventing aminoglycoside kinase mediated antibiotic resistance.Polymer assisted entrapment of netilmicin in PLGA nanoparticles for sustained antibacterial activity.Changes in the inner ear structures in cystic fibrosis patients.Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres.The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis.The effect of alginate lyase on the gentamicin resistance of Pseudomonas aeruginosa in mucoid biofilms.Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection.Polymyxin Susceptibility in Pseudomonas aeruginosa Linked to the MexXY-OprM Multidrug Efflux System.High-dose ibuprofen is not associated with increased biomarkers of kidney injury in patients with cystic fibrosis.Safety of intravenous tobramycin in combination with a variety of anti-pseudomonal antibiotics in children with cystic fibrosis.Tomatidine acts in synergy with aminoglycoside antibiotics against multiresistant Staphylococcus aureus and prevents virulence gene expression.Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF.Prevalence of hearing and vestibular loss in cystic fibrosis patients exposed to aminoglycosides.Patient-specific modelling of regional tobramycin concentration levels in airways of patients with cystic fibrosis: can we dose once daily?
P2860
Q24198135-AD2C375F-E2F7-4D69-B22B-CFDCBAFA9868Q24234854-26FE0D55-053C-4C36-80F4-EAC17E7018EAQ34202579-21B65AEE-7763-4C52-AD34-21950ADBA2D2Q35106217-24F7D00B-FA33-471F-992C-CDB998910E33Q35682983-F3D91F2C-D895-4098-8CE3-326F38791257Q36446781-468626D3-626D-4ABE-9D7C-DB620ABD3300Q37358664-79778404-3B38-4F4C-B2FE-4A431D7AB478Q38117380-F4718BE3-EC7A-4834-BFCB-F3724BAD6CCAQ38955018-3BECAAB3-0701-4E54-BE73-A13E4A0ECAC3Q39066887-A433D988-FAED-459E-AFFA-11BD3BE07EDAQ40164055-2AD91B12-6FCC-4A88-A3D3-84F37F95F1F0Q40317145-56FF7155-D299-4D38-88A5-97E24D67A689Q40721650-8C6FFC97-15DA-4172-A537-5482E8AC386BQ41907356-89729BF5-BE50-4F3E-AEEA-A3208B999481Q42027703-37738034-365E-4D8E-93C7-93E9EEBFCFF8Q43555468-18952E19-B335-4509-B9E8-0C9C9464856DQ45128908-618E5DCC-76F3-4D46-97F3-1B8232B75D7DQ45988832-8001156C-8E69-4D7A-B6C5-1170DAC115BAQ47422154-193CD895-0B65-4467-973A-FB4E9A42945DQ48358705-21428769-4109-49D6-86D1-EFC1DD7D0D08Q50065144-17654E0D-ABEC-4629-BAC9-09A4FFEC965E
P2860
Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity.
@en
Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity.
@nl
type
label
Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity.
@en
Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity.
@nl
prefLabel
Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity.
@en
Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity.
@nl
P1476
Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity
@en
P2093
Alan R Smyth
Andrew Prayle
P304
P356
10.1097/MCP.0B013E32833EEBFD
P577
2010-11-01T00:00:00Z